Trending stocks today
Entrada Therapeutics, Inc. (TRDA-Q)
NASDAQ:TRDA
21.59
1.27
(6.25%) 1d
Financials
Technical Analysis
Buy, Sell or Hold?
This summary was created by AI, based on 1 opinions in the last 12 months.
Entrada Therapeutics, Inc. is a pharmaceutical company that focuses on producing clinical stage drugs to aid in the delivery of other therapeutics. They have a strong portfolio of RNA based programs and are trading at attractive valuation metrics. With a stop-loss recommendation at $13 and a target price of $21, the stock has an upside potential of 27%. The company also boasts a 32% return on equity and growing cash reserves, making it an attractive investment opportunity.
$16.390
Unknown
- «
- ‹
- 1
- ›
- »
Entrada Therapeutics, Inc.(TRDA-Q) Rating
Ranking : 1 out of 5
Bullish - Buy Signals / Votes : 0
Neutral - Hold Signals / Votes : 0
Bearish - Sell Signals / Votes : 0
Total Signals / Votes : 0
Entrada Therapeutics, Inc.(TRDA-Q) Frequently Asked Questions
What is Entrada Therapeutics, Inc. stock symbol?
Entrada Therapeutics, Inc. is a American stock, trading under the symbol TRDA-Q on the NASDAQ (TRDA). It is usually referred to as NASDAQ:TRDA or TRDA-Q
Is Entrada Therapeutics, Inc. a buy or a sell?
In the last year, there was no coverage of Entrada Therapeutics, Inc. published on Stockchase.
Is Entrada Therapeutics, Inc. a good investment or a top pick?
Entrada Therapeutics, Inc. was recommended as a Top Pick by on . Read the latest stock experts ratings for Entrada Therapeutics, Inc..
Why is Entrada Therapeutics, Inc. stock dropping?
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
Is Entrada Therapeutics, Inc. worth watching?
In the last year, there was no coverage of Entrada Therapeutics, Inc. published on Stockchase.
What is Entrada Therapeutics, Inc. stock price?
On 2024-12-06, Entrada Therapeutics, Inc. (TRDA-Q) stock closed at a price of $21.59.
This pharma company produces clinical stage drugs that aid the delivery of other therapeutics and they have been advancing a portfolio of RNA based programs. It trades at 6x trailing earnings, under 1.5x book and supports a 32% ROE and has growing cash reserves. We recommend setting a stop-loss at $13, looking to achieve $21 -- upside potential of 27%. Yield 0%
(Analysts’ price target is $21.50)